(±)-18-MC competitively inhibits α9α10 nAChRs with potencies higher than that at α3β4 and α4β2 nAChRs and directly blocks CaV2.2.
The compound (±)-18-MC is a selective antagonist of α9α10 nAChRs with higher potency than its effects on other subtypes like α3β4 and α4β2 nAChRs, and it also directly blocks the CaV2.2 channel.